The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma

Inclusion Criteria

- Age > 18 years

- ECOG PS < 3

- Histologically confirmed or radiographic evidence of recurrent/progressive high- grade
glioma after treatment with bevacizumab

- History of radiation therapy to the brain for prior diagnosis of glioma

- Planned radiation treatments at Mayo Clinic Rochester

- Provide informed written consent

- Willing to sign consent onto the Mayo Clinic Radiotherapy Patient Outcomes Registry
and Biobanking study, IRB number 15-000136 (blood draw optional)

- Willing to return to enrolling institution for follow-up during Active Monitoring
Phase of the study.

Exclusion Criteria

- More than one prior course of radiotherapy or prior prescription doses exceeding 60 Gy
to target volumes

- Unable to undergo MRI scans with contrast

- Unable to undergo an 18F-DOPA-PET scan (e.g., Parkinson's Disease, taking anti
dopaminergic, or dopamine agonist medication or less than 6 half-lives from
discontinuance of dopamine agonists.)

Note: Other potentially interfering drugs: amoxapine, amphetamine, benztropine, buproprion,
buspirone, cocaine, mazindol, methamphetamine, methylphenidate, norephedrine, phentermine,
phenylpropanolamine,selegiline, paroxetine, citalopram, and sertraline). If a patient is on
any of these drugs, list which ones on the On-Study form.

-Any of the following:

- Pregnant women

- Nursing women

- Men or women of childbearing potential who are unwilling to employ adequate
contraception